Recent findings have highlighted the high rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia, underscoring the need for vigilant monitoring and possibly adjusting antifungal therapy based on CRP levels and other biomarkers (33, 34). This evidence concerns the gene CRP and Decreased total neutrophil count.